Summit Securities Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Summit Securities Group’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-736	Closed	-$2.58K	–	1316
2025 Q4	$2.58K	Buy	+736	New	+$2.52K	﹤0.01%	950

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Summit Securities Group's RCKT Position: Q1 2026 in Review

Summit Securities Group sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 736 shares — an estimated $2.58K sold.

Summit Securities Group first reported a position in RCKT in Q4 2025 and held it in 1 quarter. The position peaked at $2.58K in Q4 2025. 199 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

Summit Securities Group reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Summit Securities Group sold 736 Rocket Pharmaceuticals shares in Q1 2026, an estimated $2.58K.
Summit Securities Group first reported a position in Rocket Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Summit Securities Group's Rocket Pharmaceuticals position peaked at $2.58K in Q4 2025.
199 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.